Optimizing the use of thiopurines in inflammatory bowel disease

Therapeutic Advances in Chronic Disease

Volumn 6, Issue 3, 2015, Pages 138-146

  Goel, Rishi M ^a   Blaker, Paul ^a   Mentzer, Alex ^a   Fong, Steven C m ^a   Sanderson, Jeremy D ^a   Marinaki, Anthony M ^b  

^a GUY'S AND ST THOMAS' NHS FOUNDATION TRUST   (United Kingdom)

^b ST THOMAS HOSPITAL   (United Kingdom)

Author keywords

Azathioprine; Crohn s disease; Drugs; Gastroenterology; Inflammatory bowel disease; Thiopurines; Ulcerative colitis

Indexed keywords

AZATHIOPRINE; C REACTIVE PROTEIN; MERCAPTOPURINE; THIOGUANINE DERIVATIVE; THIOGUANINE NUCLEOTIDE; THIOPURINE METHYLTRANSFERASE; UNCLASSIFIED DRUG;

BLOOD CELL COUNT; BONE MARROW TOXICITY; CROHN DISEASE; DRUG BIOAVAILABILITY; DRUG METABOLISM; ENZYME METABOLISM; HUMAN; HYPERPLASIA; INFLAMMATORY BOWEL DISEASE; LEUKOPENIA; META ANALYSIS (TOPIC); NODULAR REGENERATIVE HYPERPLASIA; NUCLEAR MAGNETIC RESONANCE IMAGING; PANCYTOPENIA; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; ULCERATIVE COLITIS;

EID: 84930516274     PISSN: 20406223     EISSN: 20406231     Source Type: Journal    
DOI: 10.1177/2040622315579063     Document Type: Review

References (55)

1. Aarbakke J. Janka-Schaub G. Elion G. (1997) Thiopurine biology and pharmacology. Trends Pharmacol Sci 18: 3–7.
2. Amin J. Huang B. Yoon J. Shih D. (2015) Update 2014: advances to optimize 6-mercaptopurine and azathioprine to reduce toxicity and improve efficacy in the management of IBD. Inflamm Bowel Dis 21: 445–452.
3. Ansari A. Hassan C. Duley J. Marinaki A. Shobowale-Bakre E. Seed P. et al. (2002) Thiopurine methyltransferase activity and the use of azathioprine in inflammatory bowel disease. Aliment Pharmacol Ther 16: 1743–1750.
4. Ansari A. Patel N. Sanderson J. O'Donohue J. Duley J. Florin T. (2010) Low-dose azathioprine or mercaptopurine in combination with allopurinol can bypass many adverse reactions in patients with inflammatory bowel disease. Aliment Pharmacol Ther 31: 640–647.
5. Aridizzone S. Maconi G. Russo A. Imbesi V. Colombo E. Bianchi Porro G. et al. (2006) Randomised controlled trial of azathioprine and 5-aminosalicylic acid for treatment of steroid dependent ulcerative colitis. Gut 55: 47–53.
6. Beaugerie L. Brousse N. Bouvier A. Colombel J. Lemann M. Cosnes J. et al. (2009) Lymphoproliferative disorders in patients receiving thiopurines for inflammatory bowel disease: a prospective observational cohort study. Lancet 374: 1617–1625.
7. Beigel F. Steinborn A. Schnitzler F. Tillack C. Breiteneicher S. John J. et al. (2014) Risk of malignancies in patients with inflammatory bowel disease treated with thiopurines or anti-TNF alpha antibodies. Pharmacoepidemiol Drug Saf 23: 735–744.
8. Blaker P. Arenas-Hernandez M. Marinaki A. Sanderson J. (2012) The pharmacogenetic basis of individual variation in thiopurine metabolism. J Pers Med 9: 707–725.
9. Blaker P. Arenas-Hernandez M. Smith M. Shobowale-Bakre E. Fairbanks L. Irving P. et al. (2013) Mechanism of allopurinol induced TPMT inhibition. Biochem Pharmacol 86: 539–547.
10. Chatu S. Subramanian V. Saxena S. Pollok R. (2014) The role of thiopurines in reducing the need for surgical resection in Crohn's disease: a systematic review and meta-analysis. Am J Gastroenterol 109: 23–34.
11. Colombel J. Ferrari N. Debuysere H. Marteau P. Gendre J. Bonaz B. et al. (2000) Genotypic analysis of thiopurine S-methyltransferase in patients with Crohn's disease and severe myelosuppression during azathioprine therapy. Gastroenterology 118: 1025–1030.
12. Colombel J. Sandborn W. Reinisch W. Mantzaris G. Kornbluth A. Rachmilewitz D. et al. (2010) Infliximab, azathioprine, or combination therapy for Crohn's disease. N Engl J Med 362: 1383–1395.
13. Cuffari C. Hunt S. Bayless T. (2001) Utilisation of erythrocyte 6-thioguanine metabolite levels to optimize azathioprine therapy in patients with inflammatory bowel disease. Gut 48: 642–646.
14. de Boer N. Zondervan P. Gilissen L. den Hartog G. Westerveld B. Derijks L. et al. (2007) Drug insight: pharmacology and toxicity of thiopurine therapy in patients with IBD. Nat Clin Gastroenterol Hepatol 4: 686–694.
15. Dubinsky M. Lamothe S. Yang H. Targan S. Sinnett F. Theoret Y. et al. (2000) Pharmacogenomics and metabolite measurement for 6-mercaptopurine therapy in inflammatory bowel disease. Gastroenterology 118: 705–713.
16. Dubinsky M. Yang H. Hassard P. Seidman E. Kam L. Abreu M. et al. (2002) 6-MP metabolite profiles provide a biochemical explanation for 6-MP resistance in patients with inflammatory bowel disease. Gastroenterology 122: 904–915.
17. Elion G. (1989) The purine path to chemotherapy. Science 244: 41–47.
18. Gearry R. Barclay M. (2005) Azathioprine and 6-mercaptopurine pharmacogenetics and metabolite monitoring in inflammatory bowel disease. J Gastroenterol Hepatol 20: 1149–1157.
19. Gearry R. Barclay M. Burt M. Collett J. Chapman B. Roberts R. et al. (2003) Thiopurine S-methyltransferase (TPMT) genotype does not predict adverse drug reactions to thiopurine drugs in patients with inflammatory bowel disease. Aliment Pharmacol Ther 18: 395–400.
20. Higgs J. Payne K. Roberts C. Newman W. (2010) Are patients with intermediate TPMT activity at increased risk of myelosuppression when taking thiopurine medications? Pharmacogenomics 11: 177–188.
21. Irving P. (2014) Are we using and monitoring thiopuines and biologics optimally? Digestive Diseases 32: 410–418.
22. Kamm M. de Cruz P. Wright E. Hamilton A. Ritchie K. Krejany E. et al. (2014) Optimising post-operative Crohn's disease management: best drug therapy alone versus endoscopic monitoring, disease evolution, and faecal calprotectin monitoring. The POCER study. J Crohns Colitis 8(Suppl. 1): S13.
23. Kandiel A. Fraser A. Korelitz B. Brensinger B. Lewis J. (2005) Increased risk of lymphoma among inflammatory bowel disease patients treated with azathioprine and 6-mercaptopurine. Gut 54: 1121–1125.
24. Kaskas B. Louis E. Hindorf U. Schaeffeler E. Deflandre J. Graepler F. et al. (2003) Safe treatment of thiopurine S-methyltransferase deficient Cohn's disease patients with azathioprine. Gut 52: 140–142.
25. Kennedy N. Kalla R. Warner B. Gambles C. Musy R. Reynolds S. et al. (2014) Thiopurine withdrawal during sustained clinical remission in inflammatory bowel disease: relapse and recapture rates, with predictive factors in 237 patients. Aliment Pharmacol Ther 40: 1313–1323.
26. Lémann M. Mary J. Colombel J. Duclos B. Soule J. Lerebours E. et al. (2005) A randomized, double-blind, controlled withdrawal trial in Crohn's disease patients in long-term remission on azathioprine. Gastroenterology 128: 1812–1818.
27. Leung Y. Sparrow M. Schwartz M. Hanauer S. (2009) Long term efficacy and safety of allopurinol and azathioprine or 6-mercaptopurine in patients with inflammatory bowel disease. J Crohns Colitis 3: 162–167.
28. Lopez A. Mounier M. Bouvier A. Carrat F. Maynadie M. Beaugerie L. et al. (2014) Increased risk of acute myeloid leukemias and myelodysplastic syndromes in patients who received thiopurine treatment for inflammatory bowel disease. Clin Gastroenterol Hepatol 12: 1324–1329.
29. McGovern D. Travis S. Duley J. Shobowale-Bakre E. Dalton H. (2002) Azathioprine intolerance in patients with IBD may be imidazole-related and is independent of TPMT activity. Gastroenterology 122: 838–839.
30. Moreau A. Laporte S. Del Tedesco F. Rinaudo-Gaujous M. Phelip J. Paul S. et al. (2013) Association between thiopurines metabolites levels and clinical remission in IBD patients: an updated meta-analysis. Gastroenterology 144: S-92.
31. Mowat C. Cole A. Windsor A. Ahmad T. Arnott I. Driscoll R. et al. (2010) Guidelines for the management of inflammatory bowel disease in adults. Gut 60: 571–607.
32. Musumba C. (2013) Review article: the association between nodular regenerative hyperplasia, inflammatory bowel disease and thiopurine therapy. Aliment Pharmacol Ther 38: 1025–1037.
33. Nagy F. Molnar T. Szepes Z. Farkas K. Nyari T. Lonovics J. (2008) Efficacy of 6-mercaptopurine treatment after azathioprine hypersensitivity in inflammatory bowel disease. World J Gastroenterol 14: 4342–4346.
34. Osterman M. Kundu R. Lichtenstein G. Lewis J. (2006) Association of 6-thioguanine nucleotide levels and inflammatory bowel activity: a meta-analysis. Gastroenterology 130: 1047–1053.
35. Panés J. López-Sanromán A. Bermejo F. García-Sánchez V. Esteve M. Torres Y. et al. (2013) Early azathioprine therapy is no more effective than placebo for newly diagnosed Crohn's disease. Gastroenterology 145: 766–774.
36. Pavlidis P. Ansari A. Duley J. Oancea I. Florin T. (2014) Splitting a therapeutic dose of thioguanine may avoid liver toxicity and be an efficacious treatment for severe inflammatory bowel disease: a 2-center observational cohort study. Inflamm Bowel Dis 20: 2239–2246.
37. Prefontaine E. Macdonald J. Sutherland L. (2010) Azathioprine or 6-mercaptopurine for induction of remission in Crohn's disease. Cochrane Database Syst Rev (6): CD000545.
38. Rahier J. Ben-Horin S. Chowers Y. Conlon C. de Munter P. D'Haens G. et al. (2009) European evidence-based consensus on the prevention, diagnosis and management of opportunistic infections in inflammatory bowel disease. J Crohns Colitis 3: 47–91.
39. Relling M. Gardner E. Sandborn W. Schmiegelow K. Pui C. Yee S. et al. (2011) Clinical pharmacogenetics implementation consortium guidelines for thiopurine methyltransferase genotype and thiopurine dosing. Clin Pharmacol Ther 89: 387–391.
40. Remy C. (1963) Metabolism of thiopyrimidines and thiopurines S-methylation with S-adenosylmethionine transmethylase and catabolism in mammalian tissues. J Biol Chem 238: 1078–1084.
41. Roblin X. Serre-Debeauvais F. Phelip J. Faucheron J. Hardy G. Chartier A. et al. (2005) 6-tioguanine monitoring in steroid-dependent patients with inflammatory bowel diseases receiving azathioprine. Aliment Pharmacol Ther 21: 829–839.
42. Sau A. Clarke S. Bass J. Kaiser A. Marinaki A. Nelson-Piercy C. (2007) Azathioprine and breastfeeding: is it safe? BJOG 114: 498–501.
43. Schwab M. Schaffeler E. Marx C. Fischer C. Lang T. Behrens C. et al. (2002) Azathioprine therapy and adverse drug reactions in patients with inflammatory bowel disease: impact of thiopurine S-methyltransferase polypmorphism. Pharmacogenetics 12: 429–436.
44. Seidman E. (2003) Clinical use and practical application of TPMT enzyme and 6-mercaptopurine metabolite monitoring in IBD. Rev Gastroenterol Disord 3(Suppl. 1): S30–S38.
45. Setshedi M. Epstein D. Winter T. Myer L. Watermeyer G. Hift R. (2012) Use of thiopurines in the treatment of inflammatory bowel disease is associated with an increased risk of non-melanoma skin cancer in an at-risk population: a cohort study. J Gastroenterol Hepatol 27: 385–389.
46. Shih D. Nguyen M. Zheng L. Ibanez P. Mei L. Kwan L. et al. (2012) Split-dose administration of thiopurine drugs: a novel and effective strategy for managing preferential 6-MMP metabolism. Aliment Pharmacol Ther 36: 449–458.
47. Shih D. Yoon J. Huang B. Karsan S. Melmed G. Ippoliti A. et al. (2013) Potential synergism between anti-TNF and thiopurine therapy: increased thiopurine metabolites by anti-TNF. Gastroenterology 144: S772.
48. Smith M. Blaker P. Marinaki A. Anderson S. Irving P. Sanderson J. (2012) Optimising outcome on thiopurines in inflammatory bowel disease by co-prescription of allopurinol. J Crohns Colitis 6: 905–912.
49. Sparrow M. Hande S. Friedman S. Cao D. Hanauer S. (2007) Effect of allopurinol on clinical outcomes in inflammatory bowel disease nonresponders to azathioprine or 6-mercaptopurine. Clin Gastroenterol Hepatol 5: 209–214.
50. Tiede I. Fritz G. Strand S. Poppe D. Dvorsky R. Strand D. et al. (2003) CD28-dependent Rac 1 activation is the molecular target of azathioprine in primary human CD4+ T lymphocytes. J Clin Invest 111: 1133–1145.
51. Toruner M. Loftus E. Scott Harmsen W. Zinsmeister A. Orenstein R. Sandborn W. et al. (2008) Risk factors for opportunistic infections in patients with inflammatory bowel disease. Gastroenterology 134: 929–936.
52. Treton X. Bouhnik Y. Mary J. Colombel J. Duclos B. Soule J. et al. (2009) Azathioprine withdrawal in patients with Crohn's disease maintained on prolonged remission: a high risk of relapse. Clin Gastroenterol Hepatol 7: 80–85.
53. Wenzl H. Primas C. Novacek G. Teml A. Offerlbauer-Ernst A. Högenauer C. et al. (2014) Withdrawal of long-term maintenance treatment with azathioprine tends to increase relapse risk in patients with Crohn's disease. Dig Dis Sci 8 November (epub ahead of print).
54. van Assche G. Dignass A. Reinisch W. Janneke van der Woude C. Sturm A. de Vos M. et al. (2010) The second European evidence-based Consensus on the diagnosis and management of Crohn's disease: current management. J Crohns Colitis 4: 63–101.
55. Vos A. Bakkal N. Minnee R. Casparie M. de Jong D. Dijkstra G. et al. (2011) Risk of malignant lymphoma in patients with inflammatory bowel diseases: a Dutch nationwide study. Inflamm Bowel Dis 17: 1837–1845.